A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer

NCT05241899 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Fruquintinib + RC48

Sponsor

The First Affiliated Hospital of Zhengzhou University